UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dexamethasone as a partner of isatuximab

Blood, 2021-03, Vol.137 (9), p.1133-1134

2021

Volltextzugriff (PDF)

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

Blood, 2019-08, Vol.134 (8), p.668-677

2019

Volltextzugriff (PDF)

Role of urine immunofixation in defining CR in MM

Blood, 2019-06, Vol.133 (25), p.2731-2731

2019

Volltextzugriff (PDF)

Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study

BLOOD, 2021-11, Vol.138 (Supplement 1), p.1667-1667

2021

Volltextzugriff (PDF)

Daratumumab (DARA) Subcutaneous (SC) Delivery in Relapsed or Refractory Multiple Myeloma (RRMM): Population Pharmacokinetics (PPK) and Exposure-Response (E-R) Analysis

BLOOD, 2019-11, Vol.134 (Supplement_1), p.3151-3151

2019

Volltextzugriff (PDF)

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

BLOOD, 2019-11, Vol.134 (Supplement_2), p.LBA-6-LBA-6

2019

Volltextzugriff (PDF)

A Matching-Adjusted Indirect Treatment Comparison of Daratumumab-Bortezomib-Melphalan-Prednisone Versus Lenalidomide-Dexamethasone Continuous, Lenalidomide-Dexamethasone 18 Months, and Melphalan-Prednisone-Thalidomide

Blood, 2018-11, Vol.132 (Supplement 1), p.3551-3551

2018

Volltextzugriff (PDF)

Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)

BLOOD, 2020-11, Vol.136 (Supplement 1), p.27-27

2020

Volltextzugriff (PDF)

Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO)

BLOOD, 2018-11, Vol.132 (Supplement 1), p.2006-2006

2018

Volltextzugriff (PDF)

Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study

BLOOD, 2017-12, Vol.130 (Suppl_1), p.838-838

2017

Volltextzugriff (PDF)

Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)

BLOOD, 2018-11, Vol.132 (Supplement 1), p.1995-1995

2018

Volltextzugriff (PDF)

Assessment of Multiple Myeloma Patient Preferences on Treatment Choices: An International Discrete Choice Study

Blood, 2015-12, Vol.126 (23), p.2086-2086

2015

Volltextzugriff (PDF)

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

BLOOD, 2016-12, Vol.128 (22), p.1149-1149

2016

Volltextzugriff (PDF)

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

BLOOD, 2016-12, Vol.128 (22), p.4414-4414

2016

Volltextzugriff (PDF)

The Hybrid Molecule, Edo-S101, Impairs Double Strand Breaks Repair in Multiple Myeloma and Synergizes with Bortezomib and Dexamethasone

Blood, 2015-12, Vol.126 (23), p.5354-5354

2015

Volltextzugriff (PDF)

Preliminary Report from an Exploratory Phase II Trial with Plitidepsin (Aplidin®) in Patients with Refractory/Relapsed Multiple Myeloma

Blood, 2005-11, Vol.106 (11), p.2569-2569

2005

Volltextzugriff (PDF)

Genetic Abnormalities and Patterns of Antigenic Expression in Multiple Myeloma

Blood, 2004-11, Vol.104 (11), p.1425-1425

2004

Volltextzugriff (PDF)

Allogeneic Transplantation with Identical MHC: Clinic-Pronostic Value of Discrepances of Microsatellite DNA Regions between Recipient and Donor

Blood, 2004-11, Vol.104 (11), p.3336-3336

2004

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieBlood

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Medicin Och Hälsovetenskap
(15)
Hematology
(5)
Life Sciences & Biomedicine
(5)
Science & Technology
(5)
Humans
(4)
Female
(3)
Male
(3)
Multiple Myeloma - Drug Therapy
(3)
Multiple Myeloma - Mortality
(3)
Adult
(2)
Aged
(2)
Carfilzomib
(2)
Clinical Trials And Observations
(2)
Dexamethasone - Administration & Dosage
(2)
Middle Aged
(2)
Treatment Outcome
(2)
Adolescent
(1)
American
(1)
Antibodies, Monoclonal - Administration & Dosage
(1)
Antibodies, Monoclonal - Adverse Effects
(1)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Menü

Weitere Dienste

Einstellungen

Dexamethasone as a partner of isatuximab

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

Role of urine immunofixation in defining CR in MM

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA

Predictors of unsustained measurable residual disease negativity in transplant-eligible multiple myeloma patients

Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study

Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Daratumumab (DARA) Subcutaneous (SC) Delivery in Relapsed or Refractory Multiple Myeloma (RRMM): Population Pharmacokinetics (PPK) and Exposure-Response (E-R) Analysis

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

A Matching-Adjusted Indirect Treatment Comparison of Daratumumab-Bortezomib-Melphalan-Prednisone Versus Lenalidomide-Dexamethasone Continuous, Lenalidomide-Dexamethasone 18 Months, and Melphalan-Prednisone-Thalidomide

Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba

The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone

Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study

Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Assessment of Multiple Myeloma Patient Preferences on Treatment Choices: An International Discrete Choice Study

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study

The Hybrid Molecule, Edo-S101, Impairs Double Strand Breaks Repair in Multiple Myeloma and Synergizes with Bortezomib and Dexamethasone

Preliminary Report from an Exploratory Phase II Trial with Plitidepsin (Aplidin®) in Patients with Refractory/Relapsed Multiple Myeloma

Genetic Abnormalities and Patterns of Antigenic Expression in Multiple Myeloma

Allogeneic Transplantation with Identical MHC: Clinic-Pronostic Value of Discrepances of Microsatellite DNA Regions between Recipient and Donor

Aktive Filter

Suchergebnisse filtern